Platelet-to-lymphocyte ratio as a prognostic biomarker in patients with human epidermal growth factor receptor 2-negative breast cancer undergoing taxane-carboplatin-based neoadjuvant chemotherapy.

ABSTRACT:

Background

Taxane-carboplatin-based neoadjuvant chemotherapy (NAC) improves the pathological complete response (pCR) rate in human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, its effect on long-term survival remains unclear. Reliable prognostic biomarkers are needed to guide personalized postoperative strategies.

Objectives

To evaluate the prognostic significance of the platelet-to-lymphocyte ratio (PLR) and to construct a predictive model for overall survival (OS) in this clinical setting.

Design

This was a retrospective, multicenter cohort study involving an internal development cohort and an external validation cohort.

Methods

We retrospectively analyzed 178 HER2-negative breast cancer patients treated with taxane-carboplatin N

SUBMITTER: Huang Q 

PROVIDER: S-EPMC12475336 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature